ArticleDiscover oncology2026
Long-term risk of second primary malignancy in young women with breast cancer receiving postoperative radiotherapy.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapy for young women with breast cancer (YWBC) in early stage includes surgery, radiotherapy, and endocrinotherapy. Radiation exposure, including from postoperative radiotherapy (PORT), is known to increase the risk of subsequent malignancies, particularly in younger individuals with longer life expectancy and greater tissue susceptibility. However, the long-term risk of second primary malignancy (SPM) associated with PORT specifically in YWBC remains poorly characterized.
methodsIn this retrospective cohort study using sing data from the Surveillance, Epidemiology, and End Results (SEER)-8 registries (1975-2018), we identified women aged 18-39 years diagnosed with localized or regional stage breast cancer. PORT-correlated risks were evaluated using multivariable logistic regression and Fine-Gray competing risk regression analysis.
resultsWe identified 34,580 YWBC from the SEER database for our study, including 3,036 who developed SPMs. Logistic regression analyses indicated that PORT was associated with elevated odds of second primary solid malignancies (OR = 1.59, 95% CI 1.49-1.71), including breast cancer (OR = 1.99, 95% CI 1.82-2.17), lung cancer (OR = 1.73, 95% CI 1.39-2.18), and thyroid cancer (OR = 1.22, 95% CI 1.04-1.77). The cumulative incidence of SPMs, calculated using Fine-Gray competing risk regression, revealed similar findings: women who received PORT had significantly higher cumulative incidence of all SPMs (aHR = 1.52, p < 0.001) and SPSMs (aHR = 1.54, p < 0.001), consistent with the primary analysis results. Moreover, YWBC who were Black race, not married, estrogen receptor negative and progesterone receptor negative had a higher risk of developing SPMs.
conclusionPORT for YWBC was associated with elevated risks of SPMs. The risk of PORT-related SPMs increased with a longer follow-up period, suggesting the need for long-term surveillance of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.